BioSpace News Archive

— Based upon successful completion of the GAIN Trial’s interim analysis, pipeline expansion announced for 2021 — Atuzaginstat to be studied in the PEAK trial, a new Phase 2 study for Parkinson’s disease — COR588, a novel lysine gingipain inhibitor, on track to enter the clinic in Q3 2021 — Top-line data in 643 subject Alzheimer’s disease pivotal GAIN Trial on schedule to be announced in Q4 2021

Ovation Science Inc. is pleased to announce it has received a further order for its DermSafe® hand sanitizer lotion from its distributor, Grupo Venta International, S.A. de C.V., with corporate offices in Guadalajara, Mexico.

The acquisition is intended to vertically integrate the Companys retail manufacturing capabilities to support the growth of its nutraceutical division and deliver unique products to consumers

Senda Biosciences, a therapeutics platform company creating novel categories of medicines based on a new field of science called Intersystems Biology, announced today that it has entered into a strategic collaboration with Nestlé Health Science for the development of novel nutritional therapies for a wide range of metabolic conditions, including obesity and glycemia.

Tissue Analytics, a Net Health company that provides software solutions for the wound care industry, announced that the company has partnered with Calgary, Canada-based Kent Imaging, Inc. to be the first member of its new application programming interface program.

Company’s LifePolymer Material Used in First Polymer Heart Valves Ever Approved by FDA for Use in Clinical Trials

Longeviti Neuro Solutions today announced a new 510(k) clearance by the U.S Food and Drug Administration (FDA) for the ClearFit® implant that acknowledges the use of ultrasound in post-operative imaging.

Spinal Elements, a spine technology company, announced the FDA clearance of the Lucent® XP-Curved Expandable Interbody Device.

EV Biologics Corp, OTC: YECO today announced that it has entered into an engagement agreement with the esteemed international law firm, Foley & Lardner LLP, est. 1842.

New pre-clinical histology data show that Vaxart’s oral vaccine protected against lung inflammation in hamster models An article published in Nature Medicine reports data from a collaboration with Stanford University researchers on in vitro activity of Vaxart’s COVID-19 vaccine